Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7D9QH
|
|||
| Drug Name |
CSL200
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Sickle-cell anaemia [ICD-11: 3A51; ICD-10: D57.1] | Phase 1 | [1] | |
| Company |
CSL Behring
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04091737) A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human gamma-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.